SAN50900
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 555980

CAS#: 2229050-90-0

Description: SAN50900, also known as FLT3-IN-3, is a potent and selective FLT3 inhibitor. SAN50900 displays nanomolar activity in biochem. assays and selectively blocks proliferation of AML cell lines harboring FLT3-​ITD mutations, whereas other transformed and normal human cells are several orders of magnitude less sensitive. SAN50900 was first reported in J Med Chem. 2018 May 10;61(9):3855-3869. (compd. 7d). This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digit of its CAS#) according to MedKoo Chemical Nomenclature (https://www.medkoo.com/page/naming).


Chemical Structure

img
SAN50900
CAS# 2229050-90-0

Theoretical Analysis

MedKoo Cat#: 555980
Name: SAN50900
CAS#: 2229050-90-0
Chemical Formula: C27H38N8O
Exact Mass: 490.3169
Molecular Weight: 490.656
Elemental Analysis: C, 66.09; H, 7.81; N, 22.84; O, 3.26

Price and Availability

Size Price Availability Quantity
100.0mg USD 1450.0 2 Weeks
200.0mg USD 2250.0 2 Weeks
500.0mg USD 3250.0 2 Weeks
1.0g USD 4650.0 2 Weeks
2.0g USD 5950.0 2 Weeks
Bulk inquiry

Synonym: FLT3-IN-3; FLT3-IN3; FLT3-IN 3; SAN50900; SAN-50900; SAN 50900;

IUPAC/Chemical Name: N2-((1r,4r)-4-aminocyclohexyl)-9-cyclopentyl-N6-(4-(morpholinomethyl)phenyl)-9H-purine-2,6-diamine

InChi Key: SAEGVASGMTZGFI-AQYVVDRMSA-N

InChi Code: InChI=1S/C27H38N8O/c28-20-7-11-22(12-8-20)31-27-32-25(24-26(33-27)35(18-29-24)23-3-1-2-4-23)30-21-9-5-19(6-10-21)17-34-13-15-36-16-14-34/h5-6,9-10,18,20,22-23H,1-4,7-8,11-17,28H2,(H2,30,31,32,33)/t20-,22-

SMILES Code: N[C@H](CC1)CC[C@@H]1NC2=NC3=C(N=CN3C4CCCC4)C(NC5=CC=C(CN6CCOCC6)C=C5)=N2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 490.656 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Gucký T, Řezníčková E, Radošová Muchová T, Jorda R, Klejová Z, Malínková V, Berka K, Bazgier V, Ajani H, Lepšík M, Divoký V, Kryštof V. Discovery of N2-(4-Amino-cyclohexyl)-9-cyclopentyl- N6-(4-morpholin-4-ylmethyl-phenyl)- 9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations. J Med Chem. 2018 May 10;61(9):3855-3869. doi: 10.1021/acs.jmedchem.7b01529. Epub 2018 Apr 30. PMID: 29672049.

SAN50900

100.0mg / USD 1450.0


Additional Information

FLT3 tyrosine kinase is a potential drug target in acute myeloid leukemia (AML) because patients with FLT3-​ITD mutations respond poorly to std. cytotoxic agents and there is a clear link between the disease and the oncogenic properties of FLT3. The MV4-​11 cells treated with 7d suppressed the phosphorylation of FLT3 and its downstream signaling pathways, with subsequent G1 cell cycle arrest and apoptosis. Addnl., a single dose of 7d in mice with s.c. MV4-​11 xenografts caused sustained inhibition of FLT3 and STAT5 phosphorylation over 48 h, in contrast to the shorter effect obsd. after administration of the ref. FLT3 inhibitor quizartinib.